Kolexia
Marabelle Aurelien Pédiatrie
Marabelle Aurelien
Pédiatrie
Gustave-Roussy
Villejuif, France
495 Activités
985 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire non à petites cellules Carcinome pulmonaire à petites cellules Mélanome Carcinomes Tumeurs colorectales Instabilité des microsatellites Métastase tumorale COVID-19

Collaborateurs

Voir plus
Champiat Stephane
Champiat Stephane
Gustave-Roussy, Villejuif, France
Soria Jean-Charles
Soria Jean-Charles
Gustave-Roussy, Villejuif, France
Michot Jean-Marie
Michot Jean-Marie
Gustave-Roussy, Villejuif, France
Massard Christophe
Massard Christophe
Gustave-Roussy, Villejuif, France

Industries

Voir plus
HIFIBIO
8 collaboration(s)
Dernière en 2023
Pierre Fabre
6 collaboration(s)
Dernière en 2023
Servier
5 collaboration(s)
Dernière en 2022
Roche
5 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
AcSé: Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
Essai Clinique (BMS)   26 février 2024
Forget lung, breast or prostate cancer: why tumour naming needs to change.
Nature   15 février 2024
Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers.
Cell death & disease   14 février 2024
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158): A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
Essai Clinique (Merck & Co.)   02 février 2024
6O Subcutaneous fat mass predicts progression-free survival in patients treated with antibody drug conjugates in early phase clinical trials
Abstract Book of the ESMO Targeted Anticancer Therapies Congress (TAT) 26 - 28 February 2024   01 février 2024
EVICTION: A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer
Essai Clinique (ImCheck Therapeutics)   28 décembre 2023
Immune checkpoints are predominantly co-expressed by clonally expanded CD4 FoxP3 intratumoral T-cells in primary human cancers.
Journal of experimental & clinical cancer research : CR   06 décembre 2023
Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice.
Journal for immunotherapy of cancer   13 novembre 2023
Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8 T cells in patients with advanced NSCLC.
Science advances   08 novembre 2023
1845P Exclusion of patients with psychiatric disorders from early phase oncology trials: A limited access to innovation?
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023